Published in J Immunol on August 15, 2007
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A (2015) 1.54
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 1.18
Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol (2015) 1.11
Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood (2008) 1.07
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol (2009) 1.07
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol (2014) 1.03
Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood (2011) 1.01
CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism. J Immunol (2011) 0.98
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood (2010) 0.96
CpG plus radiotherapy: a review of preclinical works leading to clinical trial. Front Oncol (2012) 0.95
Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas. Oncoimmunology (2013) 0.95
Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. Bioconjug Chem (2011) 0.95
Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol (2012) 0.90
Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. J Immunol (2013) 0.89
Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood (2009) 0.88
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood (2015) 0.87
Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res (2012) 0.86
Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy. Biomaterials (2009) 0.86
Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol (2012) 0.82
Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes. Bone Marrow Transplant (2013) 0.82
Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. J Exp Clin Cancer Res (2013) 0.80
Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists. Oncotarget (2016) 0.78
CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Lett (2015) 0.77
Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application. J Transl Med (2017) 0.75
Profile of Ronald Levy. Interview by Phillip Downey. Proc Natl Acad Sci U S A (2010) 0.75
Active immunotherapy: current state of the art in vaccine approaches for NHL. Curr Oncol Rep (2012) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 26.12
Toll-like receptors. Annu Rev Immunol (2001) 26.06
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 22.65
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol (2005) 18.32
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (2003) 17.57
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 16.26
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 14.80
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature (2008) 11.39
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 9.77
Innate immune recognition of viral infection. Nat Immunol (2006) 9.59
Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature (2004) 9.40
Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 9.37
Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol (2005) 9.17
TLR signaling pathways. Semin Immunol (2004) 9.08
Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med (2008) 9.00
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature (2007) 8.87
TLR signaling. Semin Immunol (2007) 8.16
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol (2005) 7.94
TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol (2008) 7.87
ER stress triggers apoptosis by activating BH3-only protein Bim. Cell (2007) 7.50
Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med (2003) 7.38
Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol (2009) 7.35
Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med (2003) 7.26
Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med (2007) 7.25
Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol (2007) 7.18
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol (2002) 7.07
Innate immunity to virus infection. Immunol Rev (2009) 7.04
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol (2009) 6.62
Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med (2007) 6.52
Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest (2002) 6.48
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology (2004) 6.47
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature (2008) 6.40
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol (2005) 6.13
Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity (2006) 5.98
Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci (2008) 5.95
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 5.76
Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol (2004) 5.71
Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A (2006) 5.70
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 5.70
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A (2004) 5.58
TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev (2005) 5.56
Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol (2002) 5.48
Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol (2002) 5.41
The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol (2009) 5.21
Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem (2006) 5.11
Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol (2008) 5.10
Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med (2006) 5.01
TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol (2003) 4.94
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 4.92
Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol (2005) 4.91
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med (2005) 4.85
The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol (2005) 4.83
Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature (2002) 4.81
Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest (2006) 4.72
The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol (2010) 4.66
TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity (2004) 4.50
Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. Proc Natl Acad Sci U S A (2009) 4.48
Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature (2012) 4.46
Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol (2006) 4.37
Toll-like receptors and innate immunity. Biochem Biophys Res Commun (2009) 4.26
IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol (2003) 4.25
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 4.23
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol (2002) 4.21
Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest (2007) 4.18
Autophagy in infection, inflammation and immunity. Nat Rev Immunol (2013) 4.16
Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol (2006) 4.15
The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med (2004) 4.14
Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe (2008) 4.14
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
MDA5/RIG-I and virus recognition. Curr Opin Immunol (2008) 4.05
Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity (2010) 4.03